Categories: Health

Studying the cerebrospinal fluid of patients with Alzheimer’s disease may help determine the molecular subtype of the disease – molecular diagnostics

Image: Researchers have discovered different biological variants of Alzheimer’s disease (photo courtesy of 123RF)

Scientists have made an important discovery by identifying five different biological variants of Alzheimer’s disease, each of which potentially requires unique therapeutic approaches. This finding suggests that previously tested Alzheimer’s drugs may have been mistakenly considered ineffective or only mildly beneficial because these options were not taken into account.

Alzheimer’s disease is caused by the accumulation of amyloid and tau proteins in the brain. However, this aggregation is only one aspect of the complexity of the disease. Researchers, including those from the Amsterdam UMC (Amsterdam, the Netherlands), have used innovative methods to analyze additional biological processes associated with Alzheimer’s disease. These processes, including inflammation and nerve cell growth, were studied by measuring several biomarkers in the cerebrospinal fluid of patients who had amyloid and tau accumulations. In their analysis of cerebrospinal fluid from 419 people diagnosed with Alzheimer’s disease, the researchers assessed 1,058 proteins and identified five different biological subtypes of the disease. The first subtype is characterized by increased amyloid production, while the second shows an alteration of the blood-brain barrier, decreased amyloid production, and decreased neuronal growth.

These subtypes also show differences in protein synthesis, immune system function, and the functioning of the organ responsible for producing cerebrospinal fluid. Different subgroups within these variants have been found to have different rates of disease progression. This discovery has important implications for drug research against Alzheimer’s disease. A drug that is effective for one subtype of Alzheimer’s disease may not be effective for another. For example, a drug designed to reduce amyloid production may benefit patients with high amyloid production, but may be harmful to those with low levels. There is also the possibility that patients with a certain variant of Alzheimer’s disease may experience more side effects compared to patients with other variants. The researchers’ next goal is to demonstrate that these subtypes of Alzheimer’s disease do indeed respond differently to medications. This will pave the way for more personalized and effective treatments for Alzheimer’s disease in the future.

Related links:
Amsterdam CMC

Source link

Admin

Share
Published by
Admin

Recent Posts

le meilleur et le pire des looks

Il y a eu beaucoup de satin, paillettes, froufrous et fanfreluches au menu de cette…

11 minutes ago

South Africa “Life underground is brutal, many don’t come out alive”: The underground city where illegal mining is a brutal business

image Source, reuterspicture introduction, The men leaving the Stilfontein mine are weak and sick.Item InformationAuthor,…

13 minutes ago

destroy HPV in the world

Infections caused by the human papillomavirus (HPV) are the most common sexually transmitted diseases. It…

17 minutes ago

The airlines will appeal the fine and say they will keep charging the surcharges.

The Ministry of Social Rights, Consumption and the 2030 Agenda authorized this Friday an amount…

21 minutes ago

Here’s how the smart bath of the future works

The Human Washing Machine is a smart bathtub that adapts to each person's needs. This…

24 minutes ago

Russell snatched pole from Sainz by 98k in Las Vegas and Verstappen wants the title now

George Russell won pole in F1 Las Vegas Grand Prix 2024 there's a great one…

28 minutes ago